Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.38 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15988597 | 0.82 | ALDH1A1 (0.31) | — | |
| SCHEMBL16953849 | 0.80 | CA2 (0.35) | KIF11 | |
| SCHEMBL28879597 | 0.74 | KIF11 (0.35) | ARCUL4AKIF11 | |
| SCHEMBL350376 | 0.72 | — | — | |
| SCHEMBL17046411 | 0.72 | KDM4E (0.36) | AR | |
| SCHEMBL22636009 | 0.72 | KIF11 (0.47) | ARSLC22A12KIF11PGR | |
| SCHEMBL2961647 | 0.72 | SLC22A12 (0.35) | SLC22A12 | |
| SCHEMBL82438 | 0.70 | TDP1 (0.34) | KIF11 | |
| SCHEMBL81363 | 0.70 | ALDH1A1 (0.39) | SLC22A12KIF11 | |
| SCHEMBL328971 | 0.70 | TSHR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-12-15 | — | — | US | claimed |
| WO-2016201052-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | claimed |
| WO-2023152042-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2023-08-17 | — | — | WO | disclosed |
| CN-115558231-A | FRP (fiber reinforced plastic) section composite material and preparation method thereof | 南京斯贝尔复合材料仪征有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-4017591-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3774741-B1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-08 | — | — | EP | disclosed |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | UCB Biopharma SRL (BE) | 2021-04-01 | — | — | US | disclosed |
| CN-112538273-A | Oil-resistant asphalt pavement material and preparation method thereof | 泗县邺霖建筑科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| WO-2021032687-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | WO | disclosed |
| EP-3774741-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019192992-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB BIOPHARMA SPRL (BE) | 2019-10-10 | — | — | WO | disclosed |
| US-20150045397-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-02-12 | — | — | US | disclosed |
| EP-2834216-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Catylix Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| WO-2014075077-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013152170-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013136170-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
| EP-1115700-A1 | OPTICALLY ACTIVE SUBSTITUTED N-ARYL-O-ARYLOXYALKYL-CARBAMATES | BAYER AG (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017157-A1 | OPTICALLY ACTIVE SUBSTITUTED N-ARYL-O-ARYLOXYALKYL-CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | AR 1208/4885CUL4A 1545/4885SLC22A12 3648/4885 |
| US-20150045397-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | SCN1B, CACNA1A, P2RX1 | AR 1249/4885CUL4A 2434/4885SLC22A12 957/4885 |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | G6PD, DPYD, DHODH | AR 4730/4885CUL4A 4180/4885SLC22A12 3057/4885 |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | AR 1011/4885CUL4A 1100/4885SLC22A12 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.